Worth Watching: What’s Syndax Pharmaceuticals Inc Downside After Today’s Significant Decline?

Worth Watching: What's Syndax Pharmaceuticals Inc Downside After Today's Significant Decline?

The stock of Syndax Pharmaceuticals Inc (NASDAQ:SNDX) is a huge mover today! About 134,655 shares traded hands or 44.62% up from the average. Syndax Pharmaceuticals Inc (NASDAQ:SNDX) has risen 2.23% since March 9, 2016 and is uptrending. It has underperformed by 5.19% the S&P500.
The move comes after 7 months negative chart setup for the $254.09 million company. It was reported on Oct, 12 by Barchart.com. We have $12.42 PT which if reached, will make NASDAQ:SNDX worth $35.57 million less.

Analysts await Syndax Pharmaceuticals Inc (NASDAQ:SNDX) to report earnings on November, 8. After $-0.47 actual earnings per share reported by Syndax Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 42.55% negative EPS growth.

According to Zacks Investment Research, “Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company’s product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.”

More notable recent Syndax Pharmaceuticals Inc (NASDAQ:SNDX) news were published by: Marketwatch.com which released: “Syndax Pharmaceuticals” on June 19, 2014, also Quotes.Wsj.com with their article: “News Syndax Pharmaceuticals Inc.SNDX” published on June 14, 2014, Globenewswire.com published: “Syndax Pharmaceuticals Announces Participation at Four Upcoming Investor …” on September 06, 2016. More interesting news about Syndax Pharmaceuticals Inc (NASDAQ:SNDX) were released by: Marketwatch.com and their article: “Syndax Pharmaceuticals Inc. trading above issue price in Nasdaq debut” published on March 03, 2016 as well as Seekingalpha.com‘s news article titled: “Syndax Pharmaceuticals IPO: Supported By A Strong Syndicate” with publication date: March 01, 2016.

SNDX Company Profile

Syndax Pharmaceuticals, Inc., incorporated on October 11, 2005, is a clinical stage biopharmaceutical firm focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment